Trump’s escalation with JPMorgan highlights banks reputational issues with trying to control the narrative.

Regulatory pressure and political alignment are now influencing programming stability, deal viability, and advertiser confidence one year into Trump's second presidency.

Potential 10% APR cards are symbolic compliance with Trump’s demand, not a real shift in credit pricing.

More and riskier choices require better advice.

The riff on Apple’s Mac versus PC campaign lightens the pharma tone while also leaning more into disclosures.

It targets pharma margins, PBM fees, and insurance subsidies to slash costs, which could redefine pricing power and consumer choice across the industry.

Execs at Bank of America, Citi, and Wells Fargo warn a 10% rate ceiling would stall economic growth.

Consumer credit could be radically transformed.

Apple Card, tech spending, and mobile banking are highlights.

Issuers warn of legal fights, tighter credit, and shrinking perks for premium users.

US dietary guidelines overhaul decades of low-fat advice and target added sugar.

The CDC’s new guidance muddles what’s essential, risking more missed or delayed shots.

TikTok’s 2026 looks just as uncertain as 2025: Despite new US owners, questions remain about content moderation and its algorithm

Wegovy pill offers a needle-free, lower-cost option that could broaden patient access.

Regulatory crackdowns, digital dominance, and AI adoption forced marketers to rethink strategy, spend, and compliance across the year.

Pharma TV advertising spending totaled $5.4 billion through November, surpassing 2024’s full-year spending of $5.1 billion, according to iSpot.tv data. Pharma advertisers are increasingly reallocating budgets to more targeted digital channels, but linear TV will remain.

Approved vaccines for infants to protect against a serious respiratory disease called RSV are getting new scrutiny from federal health agency officials, according to Reuters. Heightened federal scrutiny adds uncertainty for RSV manufacturers at a time when the childhood vaccine environment is already polarized.

Marc Cuban Cost Plus Drug online pharmacy founder Mark Cuban wants the Trump administration to waive generic drug regulatory approval fees, the entrepreneur told Reuters. Cuban’s push into US manufacturing could help lower prices for some high-cost generic drugs by adding competition where little currently exists.

Medicare plans to pay health tech companies for wearables, apps, and telehealth technology that improves patient outcomes via a new pilot program aimed to begin in July 2026. The government’s willingness to pay for digital health solutions signals a meaningful shift toward making these tools part of standard clinical care. But health tech makers need to prove their tools improve patient outcomes to make it into the pilot program.

The US Senate is moving to end the government shutdown, but the compromise deal leaves out guarantees to extend the Affordable Care Act (ACA) healthcare tax credits. Without ACA subsidies, younger and healthier consumers will likely drop out of the insurance pool, leaving older and higher-risk enrollees behind. That would drive up premiums and further reduce plan enrollment, putting pressure on insurers and shrinking consumer choice.